SARS-CoV-2 Variant Neutralisation Differences Analyzed With CR3022 Binding

06 Jul 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

Background. Progressive waves of coronavirus disease 2019 (COVID-19) have been driven by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants carrying mutations in the spike glycoprotein, particularly in immunodominant regions such as the receptor-binding domain (RBD) and the N-terminal domain (NTD). These mutations can alter antigenic surfaces and are associated with changes in antibody recognition and vaccine-induced protection.
Integrating experimental neutralisation data with computational analyses may contextualise variant-associated differences in antibody responses. Methods. Neutralisation responses were evaluated using a pseudovirus-based luciferase reporter assay including SARS-CoV-2 spike proteins from B.1 (Wuhan), B.1.617.2, AY.2 (Delta), and B.1.1.529 (Omicron).
Plasma samples from three cohorts: naturally infected (I), vaccinated (V), and vaccinated-infected individuals (V+I), along with RBD-directed monoclonal antibody CR3022, were assessed to determine neutralizing titres (NT50). In parallel, spike sequences were analysed using epitope prediction, antigenicity profiling, and structural modelling. Docking simulations of CR3022 with variant RBDs were performed using HADDOCK, and binding parameters were estimated using PRODIGY.Results.
Neutralisation responses varied across cohorts and viral variants, reflecting differences in immune exposure history.

Clinical Editorial

Frontiers in Immunology published a clinical update in Infectious Disease on 06 Jul 2026.

The item focuses on Structural and functional dissection of neutralisation differences among SARS-CoV-2 variants using antigenicity prediction and CR3022 binding analysis.

Review the original article for the full source wording and details.